Intercept Pharma (NASDAQ: ICPT) announced its plans for an international Phase 3 trial of obeticholic acid (OCA), the company's lead ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Barclays Starts Intercept Pharmaceuticals (ICPT) at OverweightMay 21, 2015 6:35 AM Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Wedbush Amid Trial DesignMay 19, 2015 12:53 PM BofA/Merrill Lynch Downgrades Intercept (ICPT) to Neutral on Lack of CatalystsMay 19, 2015 11:51 AM Intercept (ICPT) NASH Study to be Larger, Riskier and Delayed, Leerink Partners SaysMay 19, 2015 11:51 AM BMO Capital Says Buy Intercept Pharmaceuticals (ICPT) on Weakness Related to Trial DesignMay 19, 2015 11:03 AM Intercept (ICPT) Bearish Concerns Tied to Trial Size; RBC Reiterates OutperformMay 19, 2015 9:24 AM Intercept's (ICPT) OCA Ph3 Trial Design or Size Not Seen as Surprise - Deutsche BankMay 19, 2015 8:36 AM Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASHMay 19, 2015 6:00 AM Form 4 INTERCEPT PHARMACEUTICAL For: May 14 Filed by: Pruzanski MarkMay 18, 2015 9:01 PM